Medopharm

Medopharm Private Limited, established in 1970 by the late Shri Mohanmulji Chordia, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of affordable medicines. Headquartered in Chennai, Tamil Nadu, India, Medopharm has expanded its operations over five decades to become a significant player in the global pharmaceutical industry. The company is privately held and is part of the Chordia Group, which encompasses diverse industries such as pharmaceuticals, packaging, food, and distribution, with an estimated valuation of USD 320 million.

As of February 28, 2025, Medopharm employed approximately 462 individuals. The company's product portfolio includes over 300 pharmaceutical products across various therapeutic areas, including antibiotics, cardiology, central nervous system (CNS) disorders, and anti-diabetics. Medopharm exports its products to more than 100 countries, reflecting its extensive global reach.

Medopharm operates four manufacturing facilities: three in India and one in Sudan. In India, the facilities are located in Chennai, Tamil Nadu, and Malur, Karnataka. The Chennai facility is approved by multiple regulatory bodies, including the UK Medicines and Healthcare products Regulatory Agency (MHRA), cGMP, and the Ministry of Health of various countries. The Malur facility is also approved by the Ministry of Health of several countries.

The manufacturing units are equipped with state-of-the-art infrastructure to produce a diverse range of pharmaceutical products, including tablets, capsules, dry syrups, and oral suspensions. Medopharm is recognized as the only company in India utilizing aqueous coating technology on tablets, highlighting its commitment to innovation in pharmaceutical manufacturing.

Medopharm is led by a team of experienced professionals committed to the company's mission of providing affordable and high-quality medicines globally. The leadership team includes:

• Ranjitmal Chordia: Chairman
• Sampath Mal Chordia: Founding Partner
• Sanjay Dasmohapatra: Chief Operating Officer

These leaders, along with other key executives, drive Medopharm's strategic direction and operational excellence.

Medopharm has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by various regulatory agencies, such as the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards.

In the United States, Medopharm's products are subject to the Food and Drug Administration (FDA) regulations. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, Medopharm's adherence to global quality standards suggests a commitment to meeting regulatory requirements in these markets.

In the European Union, Medopharm's products are manufactured in compliance with Good Manufacturing Practice (GMP) standards, as evidenced by approvals from the UK MHRA and other European regulatory bodies. This compliance facilitates market access within the EU.

Medopharm has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by various regulatory agencies in countries such as Uganda, Tanzania, Nigeria, Zimbabwe, Malawi, Ethiopia, Ghana, Kenya, Congo, Ivory Coast, and by delegations from the Ministry of Health and WHO cGMP.

Additionally, Medopharm has a manufacturing unit in Sudan, further enhancing its presence in the African market. The company's commitment to quality and compliance with international standards has facilitated its expansion into these regions, enabling access to a broader patient population.

Medopharm's geographic strategy demonstrates a balanced approach to market diversification and risk management. The company's operations span across India, Africa, Latin America, and Southeast Asia, reducing dependence on any single market and mitigating concentration risks. This diversification allows Medopharm to leverage growth opportunities in various regions while maintaining a stable revenue base.

The strategic direction includes plans to commission additional manufacturing units both domestically and internationally, with proposed locations in the Gulf Cooperation Council (GCC) region and Africa. This expansion aims to enhance production capabilities and strengthen the company's global presence.

Specific details regarding Medopharm's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. However, the company's adherence to international quality standards, including approvals from the UK MHRA and other regulatory bodies, indicates a commitment to meeting global regulatory requirements. Medopharm's focus on quality assurance and compliance suggests that it is well-positioned to navigate the regulatory landscape in the United States.

Medopharm's manufacturing facilities are approved by various regulatory agencies, including the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards. The company's commitment to quality is further demonstrated by its adherence to WHO cGMP guidelines, as evidenced by approvals from the Ministry of Health and WHO cGMP in countries such as Uganda, Tanzania, Nigeria, Zimbabwe, Malawi, Ethiopia, Ghana, Kenya, Congo, Ivory Coast, and by delegations from the Ministry of Health and WHO cGMP.

Medopharm's manufacturing facilities are approved by various regulatory agencies, including the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards. The company's commitment to quality is further demonstrated by its adherence to WHO cGMP guidelines, as evidenced by approvals from the Ministry of Health and WHO cGMP in countries such as Uganda, Tanzania, Nigeria, Zimbabwe, Malawi, Ethiopia, Ghana, Kenya, Congo, Ivory Coast, and by delegations from the Ministry of Health and WHO cGMP.

Specific details regarding recent regulatory actions, such as Form 483 observations, warning letters, or import alerts, are not publicly available. However, Medopharm's adherence to international quality standards and approvals from various regulatory agencies suggest a strong compliance record. The company's commitment to quality assurance and compliance with global standards indicates proactive measures to maintain regulatory compliance.

Medopharm operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific market share data is not publicly available, Medopharm's extensive product portfolio, global presence, and commitment to quality position it as a significant player in the market. The company's focus on affordable medicines and strategic partnerships further enhance its competitive edge.

Medopharm's key differentiators include its extensive experience of over five decades in pharmaceutical manufacturing, a diverse product portfolio across various therapeutic areas, and a strong commitment to quality assurance. The company's unique use of aqueous coating technology on tablets and its adherence to international quality standards set it apart in the industry.

Medopharm's current strategic direction focuses on expanding its global footprint through the establishment of additional manufacturing units both domestically and internationally. The company's emphasis on contract manufacturing and branded generics aligns with its goal to be a trusted partner for global pharmaceutical companies. Future outlooks include further diversification of its product portfolio and strengthening its presence in emerging markets.

Medopharm has a significant track record in pharmaceutical manufacturing, with over 300 products in its portfolio and exports to more than 100 countries. The company's manufacturing facilities are approved by various regulatory agencies, including the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards. Medopharm's commitment to quality assurance and environmental protection further underscores its reliability as a supplier.

Importers should verify the following certifications when considering Medopharm as a supplier:

• FDA Approval: To ensure compliance with U.S. regulations, verify FDA facility registrations and approved ANDAs.
• WHO-GMP Certification: Confirm adherence to World Health Organization Good Manufacturing Practice standards.
• EU GMP Certification: Ensure compliance with European Union Good Manufacturing Practice standards.
• ISO